Pathophysiology of volume overload in acute heart failure syndromes

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Pang, Peter S ^a   Levy, Philip ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN II; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TOLVAPTAN; VASOPRESSIN;

ACUTE HEART FAILURE; BODY WEIGHT; HEART FAILURE; HEART OUTPUT; HOSPITALIZATION; HUMAN; HYPERVOLEMIA; KIDNEY DISEASE; KIDNEY PERFUSION; LUNG CONGESTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE; ULTRAFILTRATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 77955127023     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00167.x     Document Type: Review

References (46)

1. Adams JKF, Fonarow GC, Emerman CL. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149(2):209-216.
2. Gheorghiade M, Filippatos G, De Luca L. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006, 119(12 suppl 1):S3-S10.
3. Ahmed A, Allman RM, Fonarow GC. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 2008, 14(3):211-218.
4. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007, 154(2):260-266.
5. Solomon SD, Dobson J, Pocock S. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116(13):1482-1487.
6. Acute Decompensated Heart Failure National Registry(ADHERE®) Core Module Q1 2006 Final Cumulative National Benchmark Report. Scios, Inc; 2006
7. Nieminen MS, Brutsaert D, Dickstein K. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27(22):2725-2736.
8. Hunt SA, Abraham WT, Chin MH. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53(15):e1-e90.
9. Schrier RW, Arroyo V, Bernardi M. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8(5):1151-1157.
10. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988, 319(17):1127-1134.
11. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988, 319(16):1065-1072.
12. Sica DA. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 2006, 73(Suppl 2):S2-S7. discussion S30-3
13. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 2010, 362(3):228-238.
14. Francis GS, Goldsmith SR, Levine TB. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101(3):370-377.
15. Inscho EW. Lewis K. Dahl Memorial Lecture. Mysteries of renal autoregulation. Hypertension 2009, 53(2):299-306.
16. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007, 356(19):1966-1978.
17. Ronco C, Haapio M, House AA. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52(19):1527-1539.
18. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008, 34(5):957-962.
19. Heywood JT, Fonarow GC, Costanzo MR. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13(6):422-430.
20. Jackson CE, Solomon SD, Gerstein HC. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009, 374(9689):543-550.
21. Mullens W, Abrahams Z, Francis GS. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009, 53(7):589-596.
22. Mullens W, Abrahams Z, Skouri HN. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008, 51(3):300-306.
23. Damman K, Navis G, Smilde TD. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007, 9(9):872-878.
24. Damman K, van Deursen VM, Navis G. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009, 53(7):582-588.
25. Nass O, Rosman H, al-Khaled N. Relation of left ventricular chamber shape in patients with low (< or = 40%) ejection fraction to severity of functional mitral regurgitation. Am J Cardiol 1995, 76(5):402-404.
26. Rimoldi SF, Yuzefpolskaya M, Allemann Y. Flash pulmonary edema. Prog Cardiovasc Dis 2009, 52(3):249-259.
27. Milo O, Cotter G, Kaluski E. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol 2003, 92(2):222-226.
28. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992, 54:227-241.
29. Finley JJt, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008, 118(4):410-421.
30. Goldsmith SR, Francis GS, Cowley AW. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983, 1(6):1385-1390.
31. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82(5):1724-1729.
32. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005, 46(10):1785-1791.
33. Maisel A, Mueller C, Adams K. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008, 10(9):824-839.
34. Cotter G, Felker GM, Adams KF. The pathophysiology of acute heart failure--is it all about fluid accumulation? Am Heart J 2008, 155(1):9-18.
35. Cotter G, Metra M, Milo-Cotter O. Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008, 10(2):165-169.
36. Gheorghiade M, Abraham WT, Albert NM. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296(18):2217-2226.
37. Yu CM, Wang L, Chau E. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005, 112(6):841-848.
38. Adamson PB, Magalski A, Braunschweig F. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003, 41(4):565-571.
39. Chaudhry SI, Wang Y, Concato J. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007, 116(14):1549-1554.
40. Lucas C, Johnson W, Hamilton MA. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000, 140(6):840-847.
41. Gheorghiade M, Konstam MA, Burnett JC. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007, 297(12):1332-1343.
42. Konstam MA, Gheorghiade M, Burnett JC. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007, 297(12):1319-1331.
43. Mehta RH, Rogers JG, Hasselblad V. Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. Am J Cardiol 2009, 103(1):76-81.
44. Costanzo MR, Guglin ME, Saltzberg MT. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49(6):675-683.
45. Blair JE, Khan S, Konstam MA. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009, 30(13):1666-1673.
46. Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001, 96:122-131.